Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted February 11, 2008
Diabetes Study Partially Halted After Deaths
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Member Program Contributor
That more people died in the "tight" control group is true, but was it tight control that was responsible or could it have been the means by which it was controlled?  It was not rosigitazone (Avandia) or hypoglycemia responsible for the deaths, according to the articles (the scientific article...
Posted February 11, 2008
Teva wins FDA OK to sell generic Fosamax
Analysis of: Teva wins FDA OK to sell generic Fosamax | www.reuters.com
Author: GLG Member Program Contributor
The first supplier to the market of a generic drug typically holds the market share.
Posted February 11, 2008
Diabetes Study Partially Halted After Deaths
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Member Program Contributor
I beleive that this  announcement is premature and more about being too preacutious in the present litigenous environment. Sevral variable factors may responsible for the outcomes and not just the strict glycemic control.
Posted February 8, 2008
Teva wins FDA OK to sell generic Fosamax
Analysis of: Teva wins FDA OK to sell generic Fosamax | www.reuters.com
Author: GLG Member Program Contributor
There is no loss here with fosamax going generic. The most to gain will be the PBMs and managed care as this will be the bisphosphinate to order.
Kenneth Algazy Posted February 8, 2008
Diabetes Mellitus Trial: Disclaimer: I am not a diabetes expert but I have been a physician x 39 years....
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."
Posted February 8, 2008
Warning on A1C Targets and Diabetes Death in ACCORD Trial
Analysis of: Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Author: Joseph Bass, Division Head of Endocrinology and Metabolism Evanston Northwestern Healthcare
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
Posted February 7, 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Analysis of: Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) | www.pipelinereview.com
Author: GLG Member Program Contributor
Avoiding the risk of Bisphosphonate related osteonecrosis Implication of Fosamax in cases of bisphosphonate related osteonerosis involving jaw bones
Posted February 7, 2008
Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: GLG Member Program Contributor
Galvus was not approved in a once per day 100 mg version for Europe, which puts it as a disadvantage to Merck's Januvia. To boot, there are liver testing requirements that will also be a drag. 
Posted February 5, 2008
Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism Evanston Northwestern Healthcare
Oral therapies improve complianceEU approval of Galvus does not erase US doubts
Posted February 4, 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Analysis of: Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) | www.pipelinereview.com
Author: GLG Member Program Contributor
What was missing in the article is as important as what was published.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 341

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics